CASI Ph.: targeting 50% growth in Evomela sales

"CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted."  

https://www.casipharmaceuticals.com/  

Zahlen für Q3/21

• Umsatz 8 Mio. $
• Verlust 10 Mio. $
• Cash 53 Mio. $
• MK 115 Mio. $

https://www.sec.gov/ix?doc=/Archives/edgar/data/...i-20210930x10q.htm

Insider-Käufe

https://www.sec.gov/Archives/edgar/data/895051/...2133523-1_4seq1.xml

 

1/10 RS im Anmarsch

https://casipharmaceuticals.com/...cals-announces-reverse-stock-split